PD-L1 inhibitors are a class of immunotherapy drugs designed to block the interaction between the protein PD-L1 on tumor cells and PD-1 on T-cells. This interaction typically helps cancer cells evade the immune system. By blocking it, PD-L1 inhibitors enable the immune system to recognize and attack cancer cells more effectively.
